

# Contents

Abstract .....	I
Resumen.....	III
Resum .....	V
Acronyms.....	VII
Chapter 1. Introduction.....	1
1.1. Motivation .....	1
1.2. Research Questions and Objectives .....	2
1.3. Thesis contributions .....	5
1.3.1. <i>Main Contributions</i> .....	5
1.3.2. <i>Scientific publications</i> .....	7
1.3.3. <i>Clinical studies and Datasets</i> .....	11
1.4. Projects and partners .....	13
1.5. International research stay .....	14
1.6. Thesis outline .....	15
Chapter 2. Rationale .....	17
2.1. Astrocytoma grade 4.....	17
2.1.1. <i>Astrocytoma grade 4: a particularly challenging medical problem</i> .....	17
2.1.2. <i>Differentiating between GBM IDH-wt and astrocytoma IDH-mut gr4</i> .....	19
2.2. Treatment of patients with astrocytomas grade 4 .....	21
2.2.1. <i>Standard treatment</i> .....	21
2.2.2. <i>Immunotherapies</i> .....	25
2.2.3. <i>Antiangiogenic treatment</i> .....	28
2.3. Heterogeneity in astrocytoma grade 4: At interpatient, intratumor, and longitudinal levels.....	30
2.3.1. <i>Interpatient heterogeneity</i> .....	30
2.3.2. <i>Intratumor heterogeneity</i> .....	32
2.3.3. <i>Longitudinal heterogeneity</i> .....	34
2.3.4. <i>Advanced approaches to address heterogeneity</i> .....	34
2.3.5. <i>Vascular heterogeneity</i> .....	36
2.4. Magnetic Resonance Imaging.....	36

2.4.1. MRI mechanism.....	37
2.4.2. Anatomical MRI.....	38
2.4.3. DSC Perfusion MRI.....	39
2.5. Glioma segmentation methodologies.....	41
2.6. Vascular heterogeneity assessment method: ONCOhabitats.....	42
2.7. Potential applications of DSC biomarkers.....	45
2.7.1. Patient prognosis and stratification.....	45
2.7.2. Monitoring of treatment response and prediction of tumor relapse.....	45
2.8. Next-generation sequencing in Astrocytoma grade 4.....	47
2.8.1. Genome sequencing.....	48
2.8.2. Transcriptome sequencing.....	49
2.9. Survival Analysis.....	50
2.9.1. Type of events.....	51
2.9.2. Kaplan Meier survival estimate.....	52
2.9.3. Log-rank test.....	53
PART I. Tumor Characterization and Classification.....	55
Chapter 3. Local detection of microvascular proliferation using MRI-DSC biomarkers.....	56
3.1. Introduction.....	57
3.2. Material and Methods.....	58
3.2.1. Clinical data collection .....	58
3.2.3. Patient and Tumor selection .....	59
3.2.3. MRI acquisition and processing.....	61
3.2.4. Tissue Processing and Histological Staining.....	62
3.2.5. Image overlay, mask generation, and image markers.....	64
3.2.6. Study variables .....	65
3.2.7. Histopathological and Radiologic correlation between MVA and rCBV in IDH-wildtype glioblastoma.....	66
3.2.8. Differences of rCBV according to the presence or absence of microvessels in IDH-wildtype glioblastomas .....	66
3.2.9. Differences in rCBV between IDH-mutant astrocytoma and IDH-wildtype glioblastomas .....	66
3.3. Results.....	66
3.3.1. Included Patients.....	66

3.3.2. <i>Included Blocks</i> .....	67
3.3.3. <i>Histopathological and radiologic correlation between MVA and rCBV in IDH-wildtype glioblastomas</i> .....	68
3.3.4. <i>Differences in rCBV according to the presence or absence of microvessels in IDH-wildtype glioblastomas</i> .....	70
3.3.5. <i>Differences in rCBV between IDH-wildtype glioblastomas and IDH-mutant astrocytoma</i> .....	71
3.4. Discussion.....	72
3.5. Conclusions.....	74
Chapter 4. Vascular differences between glioblastoma <i>IDH-wildtype</i> and astrocytomas <i>IDH-mutant</i> grade 4 at imaging and transcriptomic levels.....	76
4.1. Introduction.....	77
4.2. Material and Methods.....	78
4.2.1. <i>Study cohorts</i> .....	78
4.2.2. <i>MRI data</i> .....	78
4.2.3. <i>RNA data</i> .....	80
4.2.4. <i>Statistical Analyses</i> .....	80
4.3. Results.....	81
4.3.1. <i>Detection of relevant prognostic demographic and clinical variables</i> .....	81
4.3.2. <i>Cohorts' description</i> .....	81
4.3.3. <i>Correlation between imaging vascular biomarkers and overall survival</i> .....	84
4.3.4. <i>Distinct transcriptome between IDH-wildtype glioblastoma and IDH-mutant astrocytoma grade 4</i> .....	86
4.4. Discussion.....	88
4.5. Conclusions.....	89
PART II. Patient Prognosis Estimation and Stratification.....	91
Chapter 5. Multicenter validation of calculation and prognostic application of MRI-DSC biomarkers of vascular habitats.....	92
5.1. Introduction.....	92
5.2. Material and Methods.....	94
5.2.1. <i>Patient Selection</i> .....	94
5.2.2. <i>MRI</i> .....	94
5.2.3. <i>GBM Vascular Heterogeneity Assessment Through HTS Habitats</i> .....	94
5.2.4. <i>Association Between Patient OS and HTS Markers (Entire Cohort)</i> .....	95
5.2.5. <i>Intercenter Association Between Patient OS and HTS Markers</i> .....	95

5.3. Results.....	96
5.3.1. <i>Description of patient cohort</i> .....	96
5.3.2. <i>Association Between Patient OS and HTS Markers (Entire Cohort)</i> .....	97
5.3.3. <i>Intercenter Association Between Patient OS and HTS markers (per center)</i> .....	100
5.4. Discussion.....	102
5.5. Conclusions.....	104
Chapter 6. <i>Effect of tumor vascularity on patient survival over time. Comparison between long- and short-term survivors</i> .....	105
6.1. Introduction.....	105
6.2. Materials and Methods.....	107
6.2.1. <i>Patient information</i> .....	107
6.2.2. <i>MRI</i> .....	108
6.2.3. <i>Processing of MRI and vascular markers</i> .....	109
6.2.4. <i>Statistical analyses</i> .....	110
6.3. Results.....	111
6.3.1. <i>Description of the entire cohort, and the LTS and STS groups</i> .....	111
6.3.2. <i>Differences between LTSs and STSs and the effect of rCBV on patient survival</i> .....	112
6.4. Discussion.....	117
6.5. Conclusions.....	120
PART III. Treatment Responses Assessment.....	121
Chapter 7. <i>Towards personalized Temozolomide treatment considering tumor vascularity and MGMT methylation status</i> .....	122
7.1. Introduction.....	123
7.2. Material and Methods.....	124
7.2.1. <i>Patient information</i> .....	124
7.2.2. <i>MRI</i> .....	125
7.2.3. <i>DNA extraction and assessment of MGMT methylation</i> .....	127
7.2.4. <i>Statistical Analyses</i> .....	127
7.3. Results.....	129
7.3.1. <i>Study cohort</i> .....	129
7.3.2. <i>Lack of benefit of Temozolomide for MGMT methylated patients with high vascular tumors</i> .....	130

7.3.3. Benefit of adjuvant Temozolomide cycles in different groups of glioblastoma patients.....	132
7.4. Discussion.....	135
7.5. Conclusions.....	137
Chapter 8. Glioblastomas IDH-wildtype located in left cerebral hemisphere present most advantageous immune response to anti-PD-1 treatment.....	138
8.1. Introduction .....	138
8.2. Material and Methods.....	139
8.2.1. Patient Information.....	139
8.2.2. Sequencing and mapping.....	139
8.2.3. Somatic mutations.....	140
8.2.4. Analysis of copy number changes.....	140
8.2.5. Gene expression analysis.....	140
8.2.6. Quantitative multiplex immunofluorescence (qmIF) analysis.....	140
8.2.7. Statistical Analysis.....	141
8.3. Results.....	141
8.3.1. Evaluation of demographic and clinical features as predictors of anti-PD1 response .....	141
8.3.2. Patients with glioblastoma located at the left cerebral hemisphere are more likely to respond to anti-PD-1 treatment.....	143
8.3.3. Lack of benefit in terms of overall survival when providing anti-PD1 to patients with glioblastoma located at the right hemisphere .....	144
8.3.4. Molecular basis of differences in survival and anti-PD1 response between tumors located at the right and left hemispheres .....	145
8.3.5. Differences in immune cells infiltration between tumors located at right and left hemispheres.....	147
8.3.6. Tumor hemisphere is more correlated with anti-PD1 response than <i>PTEN</i> mutation and specific CNVs detected .....	148
8.4. Discussion.....	149
8.5. Conclusions.....	151
Part IV. Clinical Studies Implementation and Datasets reation.....	153
Chapter 9. Clinical studies and protocols design and implementation.....	154
9.1. Design and implementation of the <i>BIOhabitats</i> study (NCT05375318).....	154
9.1.1 <i>Background</i> .....	154
9.1.2 <i>Participating centers</i> .....	155

9.1.3. <i>Study Design</i> .....	155
9.1.4. <i>Hypothesis and objectives</i> .....	155
9.1.6. <i>Implementation</i> .....	163
9.1.7. <i>Conclusions</i> .....	167
9.2. Other clinical studies and datasets.....	167
9.1.5. <i>Methodology</i> .....	156
Chapter 10. <i>Concluding remarks and recommendations</i> .....	170
10.1. <i>Concluding remarks</i> .....	170
10.2. <i>Recommendations and future directions</i> .....	173
Bibliography.....	176
Appendix A.....	192
Appendix B.....	196
Appendix C.....	199
Appendix D.....	204
Appendix E.....	206
Appendix F.....	209